Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Mina R, Falcone AP, Bringhen S, Liberati AM, Pescosta N, Petrucci MT, Ciccone G, Capra A, Patriarca F, Rota-Scalabrini D, Bonello F, Musolino C, Cea M, Zambello R, Tacchetti P, Belotti A, Cellini C, Paris L, Grasso M, Aquino S, De Paoli L, De Sabbata G, Ballanti S, Offidani M, Boccadoro M, Monaco F, Corradini P, Larocca A. Mina R, et al. Among authors: cea m. Blood Cancer J. 2021 Dec 7;11(12):197. doi: 10.1038/s41408-021-00590-5. Blood Cancer J. 2021. PMID: 34876566 Free PMC article. Clinical Trial. No abstract available.
Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.
Soncini D, Minetto P, Martinuzzi C, Becherini P, Fenu V, Guolo F, Todoerti K, Calice G, Contini P, Miglino M, Rivoli G, Aquino S, Dominietto A, Cagnetta A, Passalacqua M, Bruzzone S, Nencioni A, Zucchetti M, Ceruti T, Neri A, Lemoli RM, Cea M. Soncini D, et al. Among authors: cea m. Blood Adv. 2020 Sep 22;4(18):4312-4326. doi: 10.1182/bloodadvances.2020001639. Blood Adv. 2020. PMID: 32915979 Free PMC article.
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S, Tacchetti P, Pantani L, Mancuso K, Rizzello I, di Giovanni Bezzi C, Scalese M, Dozza L, Marzocchi G, Martello M, Barilà G, Antonioli E, Staderini M, Buda G, Petrini M, Cea M, Quaresima M, Furlan A, Bonalumi A, Cavo M, Zamagni E. Rocchi S, et al. Among authors: cea m. Hematol Oncol. 2021 Feb;39(1):41-50. doi: 10.1002/hon.2820. Epub 2020 Nov 1. Hematol Oncol. 2021. PMID: 33085797 Clinical Trial.
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.
Rizzello I, Cavo M, Dozza L, Rivolti E, Petrucci MT, De Stefano V, Antonioli E, Tosi P, D'Agostino M, Morè S, Gozzetti A, Cea M, Barbato S, Tacchetti P, Pantani L, Mancuso K, Rocchi S, De Cicco G, Fusco A, Zamagni E. Rizzello I, et al. Among authors: cea m. Leuk Lymphoma. 2021 Aug;62(8):1897-1906. doi: 10.1080/10428194.2021.1897805. Epub 2021 Mar 18. Leuk Lymphoma. 2021. PMID: 33733993
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment.
Soncini D, Martinuzzi C, Becherini P, Gelli E, Ruberti S, Todoerti K, Mastracci L, Contini P, Cagnetta A, Laudisi A, Guolo F, Minetto P, Miglino M, Aquino S, Varaldo R, Reverberi D, Formica M, Passalacqua M, Nencioni A, Neri A, Samur MK, Munshi NC, Fulciniti M, Lemoli RM, Cea M. Soncini D, et al. Among authors: cea m. Haematologica. 2022 Jun 1;107(6):1410-1426. doi: 10.3324/haematol.2021.279276. Haematologica. 2022. PMID: 34670358 Free PMC article.
Radiomics and Artificial Intelligence for Outcome Prediction in Multiple Myeloma Patients Undergoing Autologous Transplantation: A Feasibility Study with CT Data.
Schenone D, Dominietto A, Campi C, Frassoni F, Cea M, Aquino S, Angelucci E, Rossi F, Torri L, Bignotti B, Tagliafico AS, Piana M. Schenone D, et al. Among authors: cea m. Diagnostics (Basel). 2021 Sep 24;11(10):1759. doi: 10.3390/diagnostics11101759. Diagnostics (Basel). 2021. PMID: 34679456 Free PMC article.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M. Gay F, et al. Among authors: cea m. Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. Lancet Oncol. 2021. PMID: 34774221 Free article. Clinical Trial.
Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma.
Gelli E, Soncini D, Becherini P, Martinuzzi C, Todoerti K, Cagnetta A, Aquino S, Guolo F, Miglino M, Bruzzone S, Nencioni A, Neri A, Lemoli RM, Cea M. Gelli E, et al. Among authors: cea m. Blood Adv. 2023 Jul 25;7(14):3472-3478. doi: 10.1182/bloodadvances.2022009035. Blood Adv. 2023. PMID: 36897214 Free PMC article. No abstract available.
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC. Tai YT, et al. Among authors: cea m. Blood. 2014 May 15;123(20):3128-38. doi: 10.1182/blood-2013-10-535088. Epub 2014 Feb 25. Blood. 2014. PMID: 24569262 Free PMC article.
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.
Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC. Cea M, et al. Blood. 2016 Mar 3;127(9):1138-50. doi: 10.1182/blood-2015-06-649970. Epub 2015 Dec 16. Blood. 2016. PMID: 26675349 Free PMC article.
154 results